Drugs affecting body weight, body fat distribution, and metabolic function—mechanisms and possible therapeutic or preventive measures: an update.
The DOI matches its Crossref record; 123 of the 125 references it cites were found in a registry or an index.
Abstract
Purpose of review Weight gain and body fat redistribution are common side effects of many widely used drugs. We summarize recent literature on prevalence data and mechanisms associated with drug-induced body fat changes and mechanisms to prevent or treat metabolic side effects. Recent findings The highest prevalence of metabolic complications is seen with antipsychotics and antiretroviral drugs used in the treatment of HIV and may, at least partly, be responsible for the increased risk for co-morbid diseases such as diabetes, steatosis of the liver, and cardiovascular disease. The pathogenetic mechanisms leading to weight gain from antipsychotics are increasingly known and help to unravel the complex interaction that exists between psychopathology and metabolic complications. Although the classic lipodystrophy mainly occurred with older HIV drugs, also with the newer HIV treatment, weight gain seems to be a major side effect. Early detection of the metabolic consequences of drugs can lead to an early diagnosis of the complications and their treatment. Different medications, including the newer antidiabetics, are being studied in the therapy of drug-induced obesity. Future research should focus on identifying individuals at risk for metabolic side effects and on early markers to identify individuals with side effects so that timely treatment of metabolic complications can be initiated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many weight gain-promoting medications increase the risk of weight-related complications, including CVD, diabetes, and hepatic steatosis.78”
From Obesity Management in Adults: A Review (2023) · cites this paper as [78]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“All GLP-1 receptor agonists have the potential to decrease body mass index (BMI) by decreasing appetite and increasing satiety, by their interaction in brain areas involved in the homeostasis of food intake, energy expenditure, and energy balance [15].”
BackgroundMechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“In the non-HIV-infected population, weight gain and obesity are well-documented risk factors for diabetes and CVD, and to premature mortality [105].”
BackgroundAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · cited 1×
“Up to 80% of patients taking antipsychotic medication experience weight gain that exceeds their ideal body weight by 20% or more [37].”
BackgroundAntipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622 · cited 1×
“Typical or “conventional” neuroleptics (phenothiazines, butyrophenones, and thioxanthines) have been introduced since the 1950s and are effective antipsychotic drugs because they are dopamine D2 receptor antagonists, but they all have major neurological side effects [35].”
BackgroundConsensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145 · cited 2×
“ration and with the intake of clozapine in particular [40, 41].”
BackgroundMitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082 · cited 2×
“ration and with the intake of clozapine in particular [40, 41].”
BackgroundDepression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073 · cited 2×
“But psychiatric diseases also seem to share some pathophysiological brain pathways in common with those leading to weight gain and its metabolic complications, thereby creating a kind of vicious circle where each of the pathways influences the risk for the other [21].”
BackgroundIncident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016 · cited 1×
“diabetes, even without significant weight gain [83].”
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778 · cited 2×
“TZD’s improve hepatic steatosis and inflammation in patients with non-alcoholic steatohepatitis (NASH), although safety concerns including osteoporosis and bladder cancer with pioglitazone restricts its use [5, 9].”
Background
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Skeletal muscle energy metabolism in obesity
Mengeste, A. M., Rustan, A. C., & Lund, J. (2021) · Obesity · doi:10.1002/oby.23227 · Cited by 141
Koch, C. A., Sharda, P., Patel, J., Gubbi, S., Bansal, R., & Bartel, M. J. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1533-2861 · Cited by 84
Determinants of childhood obesity in China
Yuan, C., Dong, Y., Chen, H., Ma, L., Jia, L., Luo, J., Liu, Q., Hu, Y., Ma, J., & Song, Y. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00246-9 · Cited by 80
Interactions between Food and Drugs, and Nutritional Status in Renal Patients: A Narrative Review
D’Alessandro, C., Benedetti, A., Di Paolo, A., Giannese, D., & Cupisti, A. (2022) · Nutrients · doi:10.3390/nu14010212 · Cited by 66
Metadata
- Authors
- Verhaegen, A. A., & Van Gaal, L. F.
- Affiliations
- Antwerp University Hospital (BE)
- Corresponding author
- Verhaegen, Ann A.
- ORCID
- Verhaegen, Ann A.
- Venue
- Current Obesity Reports
- Published
- 2021-01-05
- Volume
- 10
- Issue
- 1
- Pages
- 1-13
- ISSN
- 2162-4968 (ISSN-L)
- OpenAlex
- W3120882979
- Cited by
- 53
- References
- 125
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 13 · 2023: 7 · 2022: 6 · 2021: 6
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Current Obesity Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- drug-induced weight gain, fat redistribution, antipsychotic drugs, antiretroviral drugs, HIV, lipodystrophy, drug-induced obesity, metabolic side effects, diabetes mellitus, hepatic steatosis, cardiovascular disease, antidiabetic drugs
- MeSH terms
- Adrenal Cortex Hormones, Animals, Antidepressive Agents, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Humans, Insulin Resistance, Lithium, Metabolic Diseases, Obesity, Antipsychotic Agents, Weight Gain, HIV Infections, Anti-Retroviral Agents, Body Fat Distribution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drugs affecting body weight, body fat distribution, and metabolic function—mechanisms and possible therapeutic or preventive measures: an update. https://app.cochat.ai/papers/10.1007/s13679-020-00419-5
- The paper
- Verhaegen, A. A., & Van Gaal, L. F. (2021). Drugs affecting body weight, body fat distribution, and metabolic function—mechanisms and possible therapeutic or preventive measures: an update. Current Obesity Reports. https://doi.org/10.1007/s13679-020-00419-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.